Not Selling Yet, Cipla Opposes Capping MNC-led Buyouts Of Indian Firms
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Cipla Ltd. Chairman Yusuf K. Hamied has tried to temper nagging speculation over a possible sell-off to a global company like Merck & Co. or Takeda Pharmaceutical Co. Ltd. He emphatically denied holding any negotiations and claimed he has never been approached for a potential transaction
You may also be interested in...
Cipla Sees Growth In Product-Based Alliances; In Deal With Teva For Inhalers In Russia
India’s second largest drug maker draws newer strategies to keep pace with emerging markets’ growth momentum, Cipla Chairman Yusuf Hamied tells PharmAsia News in an exclusive interview.
Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry
Indian Govt Move To Scrutinize MNC Investments In Indian Firms Could have "Chilling" Effect
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry